V7A0 Stock Chart & Stats
€0.57
-€0.02(-3.10%)
At close: 4:00 PM EDT
€0.57
-€0.02(-3.10%)
Day’s Range― - ―
52-Week Range€0.48 - €1.64
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€72.95M
Enterprise Value€250.71
Total Cash (Recent Filing)€206.10M
Total Debt (Recent Filing)€367.10M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Nov 10, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding130,140,760
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)2.88
Price to Sales (P/S)0.58
P/FCF Ratio5.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.85Price Target Upside49.71% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€244.38M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables Revenue And Installed-base GrowthThe large recurring consumables mix creates revenue tied to treatment activity rather than only periodic equipment placements. Growth in the installed base expands the future consumables opportunity, supporting customer retention, visibility, and a more durable platform economics profile.
Sustained Margin And Adjusted EBITDA ImprovementMeaningful gross-margin expansion and higher adjusted EBITDA indicate that operational efficiencies, lower equipment costs, and consumables mix are improving earnings capacity. If maintained, these gains can provide more internal funding for commercial investment and reduce the effect of uneven revenue growth.
Broader Product Portfolio And European Distribution ReachExpanding SkinStylus through the existing European commercial organization broadens the company’s professional aesthetics offering without relying solely on HydraFacial. A wider product portfolio and established provider access may improve cross-selling potential and diversify longer-term growth opportunities.
Bears Say
Highly Leveraged Balance Sheet And Near-term Convertible MaturityThe high debt burden leaves limited balance-sheet cushion if operating performance weakens and restricts flexibility to fund growth or absorb setbacks. The sizeable convertible maturity adds refinancing or cash-allocation pressure, making financial stability dependent on sustained cash generation and execution.
Persistent Revenue Contraction And Weaker Equipment DemandLower equipment placements signal continued provider caution toward capital spending and can slow expansion of the installed base that supports future consumables demand. Combined with the overall sales decline, this weakens near-term growth and raises execution requirements for the platform strategy.
Unprofitable Earnings And Volatile Cash-flow ConversionPositive cash generation is not yet matched by durable bottom-line profitability, while the sharp free-cash-flow decline suggests inconsistent conversion and possible reinvestment or working-capital pressure. Ongoing losses reduce resilience and make debt repayment and strategic investment harder to sustain.
Beauty Health News
V7A0 FAQ
What was Beauty Health’s price range in the past 12 months?
Beauty Health lowest stock price was €0.48 and its highest was €1.64 in the past 12 months.
What is Beauty Health’s market cap?
Beauty Health’s market cap is €72.95M.
When is Beauty Health’s upcoming earnings report date?
Beauty Health’s upcoming earnings report date is Nov 10, 2026 which is in 39 days.
How were Beauty Health’s earnings last quarter?
Beauty Health released its earnings results on Aug 06, 2026. The company reported -€0.018 earnings per share for the quarter, beating the consensus estimate of -€0.022 by €0.004.
Is Beauty Health overvalued?
According to Wall Street analysts Beauty Health’s price is currently Undervalued.
Does Beauty Health pay dividends?
Beauty Health does not currently pay dividends.
What is Beauty Health’s EPS estimate?
Beauty Health’s EPS estimate is -0.06.
How many shares outstanding does Beauty Health have?
Beauty Health has 130,140,760 shares outstanding.
What happened to Beauty Health’s price movement after its last earnings report?
Beauty Health reported an EPS of -€0.018 in its last earnings report, beating expectations of -€0.022. Following the earnings report the stock price went down -12.308%.
Which hedge fund is a major shareholder of Beauty Health?
Currently, no hedge funds are holding shares in DE:V7A0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beauty Health Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€0.85 (49.71% Upside)
€0.85 (49.71% Upside)
Blogger Sentiment
Neutral
DE:V7A0 Sentiment 50%
Sector Average 64%
Sector Average 64%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.14%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Beauty Health
SkinHealth Systems Inc., a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions in the Americas, the Asia-Pacific, Europe, the Middle East, Africa, Canada, and Latin America. The company's flagship product is HydraFacial, which enhances the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. It also offers Syndeo devices, which are delivery systems that are designed to connect providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling and nanoneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive peptide solutions and take home sprays for treating scalp health. In addition, it operates the MyBeautyHealth mobile application for consumers to earn loyalty points and unlock savings, log skin concerns and receive personalized treatment plans, and find and connect with Hydrafacial providers, as well as offers boosters. The company was formerly known as The Beauty Health Company and changed its name to SkinHealth Systems Inc. in April 2026. The company was founded in 1997 and is headquartered in Long Beach, California.
V7A0 Company Deck
V7A0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: strong margin improvement, adjusted EBITDA upside and tangible strategic progress (rental program, product pipeline, installed‑base monetization) are positive. However, meaningful top‑line weakness — driven by an 18.4% decline in equipment revenue, continued consumables softness, regional softness in EMEA, and near‑term balance sheet and Nasdaq listing risks — tempers the outlook. Management is focused on execution and long‑term investments, but near‑term revenue and capital markets pressures balance the positives.View all DE:V7A0 earnings summariesV7A0 Stock 12 Month Forecast
Average Price Target
€0.85
▲(49.71% Upside)